Aligos Therapeutics (ALGS) Competitors

Aligos Therapeutics logo
$1.30 -0.06 (-4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$1.40 +0.10 (+7.77%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALGS vs. KZIA, EQ, GNLX, TNYA, and CBUS

Should you buy Aligos Therapeutics stock or one of its competitors? Aligos Therapeutics's main competitors and comparable companies include Novogen (KZIA), Equillium (EQ), Genelux (GNLX), Tenaya Therapeutics (TNYA), and Cibus (CBUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aligos Therapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Novogen has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -197.01%. Novogen's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovogenN/A N/A N/A
Aligos Therapeutics -197.01%-206.30%-99.45%

Novogen has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

Novogen presently has a consensus target price of $29.50, suggesting a potential upside of 455.56%. Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 2,730.88%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Novogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

30.9% of Novogen shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novogen has higher earnings, but lower revenue than Aligos Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novogen$1.23M55.99-$13.41MN/AN/A
Aligos Therapeutics$2.19M3.88-$24.19M-$6.35N/A

In the previous week, Novogen and Novogen both had 2 articles in the media. Aligos Therapeutics' average media sentiment score of 0.61 beat Novogen's score of 0.42 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Aligos Therapeutics beats Novogen on 8 of the 14 factors compared between the two stocks.

How does Aligos Therapeutics compare to Equillium?

Equillium (NASDAQ:EQ) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Equillium presently has a consensus target price of $7.13, suggesting a potential upside of 488.84%. Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 2,730.88%. Given Aligos Therapeutics' higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Equillium.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Equillium
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Equillium has higher revenue and earnings than Aligos Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Equillium$41.10M2.42-$22.40M-$0.18N/A
Aligos Therapeutics$2.19M3.88-$24.19M-$6.35N/A

Equillium has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -197.01%. Equillium's return on equity of -37.33% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
EquilliumN/A -37.33% -35.07%
Aligos Therapeutics -197.01%-206.30%-99.45%

27.1% of Equillium shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Equillium has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

In the previous week, Equillium had 4 more articles in the media than Aligos Therapeutics. MarketBeat recorded 6 mentions for Equillium and 2 mentions for Aligos Therapeutics. Equillium's average media sentiment score of 0.70 beat Aligos Therapeutics' score of 0.61 indicating that Equillium is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Equillium
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Equillium beats Aligos Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Genelux has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -197.01%. Aligos Therapeutics' return on equity of -206.30% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -224.99% -146.63%
Aligos Therapeutics -197.01%-206.30%-99.45%

Aligos Therapeutics has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K9,048.00-$32.15M-$0.86N/A
Aligos Therapeutics$2.19M3.88-$24.19M-$6.35N/A

In the previous week, Genelux had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Genelux and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.61 beat Genelux's score of -0.16 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genelux
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

37.3% of Genelux shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Genelux has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Genelux currently has a consensus price target of $20.00, indicating a potential upside of 900.00%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 2,730.88%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Genelux.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Aligos Therapeutics beats Genelux on 11 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to Tenaya Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tenaya Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -197.01%. Tenaya Therapeutics' return on equity of -88.96% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-197.01% -206.30% -99.45%
Tenaya Therapeutics N/A -88.96%-69.51%

Aligos Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M3.88-$24.19M-$6.35N/A
Tenaya TherapeuticsN/AN/A-$90.60M-$0.49N/A

Aligos Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.88, meaning that its stock price is 188% more volatile than the broader market.

In the previous week, Aligos Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 2 mentions for Aligos Therapeutics and 0 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.82 beat Aligos Therapeutics' score of 0.61 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aligos Therapeutics Positive
Tenaya Therapeutics Very Positive

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 2,730.88%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 1,139.16%. Given Aligos Therapeutics' higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than Tenaya Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Tenaya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Tenaya Therapeutics beats Aligos Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aligos Therapeutics compare to Cibus?

Aligos Therapeutics (NASDAQ:ALGS) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Comparatively, 29.9% of Cibus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aligos Therapeutics has a net margin of -197.01% compared to Cibus' net margin of -2,131.38%. Aligos Therapeutics' return on equity of -206.30% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Aligos Therapeutics-197.01% -206.30% -99.45%
Cibus -2,131.38%-526.66%-28.12%

Aligos Therapeutics has higher earnings, but lower revenue than Cibus. Cibus is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos Therapeutics$2.19M3.88-$24.19M-$6.35N/A
Cibus$3.64M29.27-$127.08M-$1.50N/A

Aligos Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Cibus has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

In the previous week, Cibus had 16 more articles in the media than Aligos Therapeutics. MarketBeat recorded 18 mentions for Cibus and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.61 beat Cibus' score of -0.31 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Cibus
2 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Aligos Therapeutics presently has a consensus price target of $38.50, indicating a potential upside of 2,730.88%. Cibus has a consensus price target of $9.00, indicating a potential upside of 547.48%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Cibus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Aligos Therapeutics beats Cibus on 10 of the 16 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALGS vs. The Competition

MetricAligos TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.13M$3.97B$7.59B$11.72B
Dividend YieldN/A3.63%2.47%4.48%
P/E Ratio-0.2024.6233.5830.13
Price / Sales3.7115.448.255.59
Price / CashN/A22.9521.0121.90
Price / Book0.724.164.443.72
Net Income-$24.19M-$24.10M$3.50B$393.88M
7 Day Performance-39.81%-8.44%-6.53%-6.07%
1 Month Performance-73.25%-6.54%-4.93%-7.38%
1 Year Performance-83.59%-6.71%-1.73%-7.48%

Aligos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALGS
Aligos Therapeutics
2.7928 of 5 stars
$1.30
-4.4%
$38.50
+2,861.5%
-80.6%$8.13M$2.19MN/A82
KZIA
Novogen
3.4676 of 5 stars
$7.40
-0.1%
$29.50
+298.6%
-12.7%$96.10M$1.23MN/A6
EQ
Equillium
2.7802 of 5 stars
$1.46
-3.0%
$7.57
+420.4%
+15.2%$95.11M$41.10MN/A14
GNLX
Genelux
2.363 of 5 stars
$1.95
-5.8%
$20.00
+925.6%
-61.9%$93.66M$10KN/A26
TNYA
Tenaya Therapeutics
2.5958 of 5 stars
$0.37
-5.9%
$4.00
+979.3%
-74.4%$89.80MN/AN/A70

Related Companies and Tools


This page (NASDAQ:ALGS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners